RESP301 clinical trials
Also written RESP301.
How each study uses RESP301 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- RESP301
- 4
Studies by the year they started
6 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 2
Thirty Respiratory Limited (4) · University of Birmingham (1) · Papworth Hospital NHS Foundation Trust (1)
Often tested with
Tested in the same studies.
Isoniazid (1) · Rifampin (1) · Pyrazinamide (1) · Ethambutol (1)
Studies
Open first, then newest update. How each study uses RESP301 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19TerminatedPhase 3University of BirminghamNCT04386070Written as RESP301
- Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With TuberculosisTerminatedPhase 2Thirty Respiratory LimitedNCT06041919Written as RESP301
- COmmunity Patients at Risk of Viral Infections Including SARS-CoV-2TerminatedPhase 2Thirty Respiratory LimitedNCT04858451Written as RESP301
- Study of a Nebulised Nitric Oxide Generating Solution in Patients With Mycobacterium AbscessusTerminatedPhase 2Papworth Hospital NHS Foundation TrustNCT05101915Written as RESP301
- PREvent Viral Exposure and Transmission Study: a COVID-19 (SARS-CoV-2) PEP Study (PREVENT)WithdrawnPhase 2/3Thirty Respiratory LimitedNCT04842331Written as RESP301 (a nitric oxide generating solution)
- A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19CompletedPhase 2/3Thirty Respiratory LimitedNCT04460183Written as RESP301, a Nitric Oxide generating solution
What changed recently
From the registry's own updates since Oct 18, 2026.
Stopped1
- Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19TerminatedNov 16, 2026NCT04386070